Hyku Biosciences

Hyku Biosciences is a private, pre-clinical stage biotech leveraging its proprietary 'Hyku Platform' to expand covalent drug discovery beyond traditional cysteine targeting. The company's integrated platform combines a proprietary library of over 6,000 covalent compounds, advanced chemoproteomics, and machine learning to identify and develop small molecules against historically 'undruggable' targets. While still in the platform validation and early discovery phase, Hyku's approach represents a significant technical advancement with the potential to unlock new therapeutic modalities across a broad range of diseases.

The Hyku Platform is an integrated discovery engine for covalent drugs targeting non-cysteine amino acids (His, Tyr, Lys). It combines a proprietary library of >6,000 covalent compounds, advanced chemoproteomics for proteome mapping, live-cell screening, and machine learning for target/compound prioritization.

Hyku competes in the expanding field of covalent drug discovery and chemoproteomics. It differentiates by focusing specifically on His, Tyr, and Lys, whereas most competitors (e.g., Relay Therapeutics, Frontier Medicines) have stronger emphasis on cysteine or allosteric targeting. It also competes for talent and funding with other platform biotechs.